![]() |
| Ho Chi Minh City Hall |
James Williams, a junior majoring in Chemistry at Princeton University, has been working through the Oxford University Clinical Research Unit in Ho Chi Minh City, Vietnam on a summer research project aimed at analyzing the role of pigs in transmitting Japanese Encephalitis Virus. He'll be returning to the states in two weeks, but before returning home James chose to guest-write this piece for TableTalk's A Blog With A View in an effort to depict the role of private research interests in the public health sector in Ho Chi Minh City.
Tucked away in a back corner of Ho Chi Minh City’s Centre for Tropical Disease, the Union Jack waves from the second floor of a nondescript building. The building looks no different from its neighbors, where HIV and malaria patients flood into the hallways on their makeshift hospital beds. But in fact, this building is different, housing labs and offices of the Wellcome Trust, a United Kingdom-based group of international biomedical researchers with associated branches in Bangkok, Kathmandu, Dar es Salaam, and Nairobi, among other places.
Wellcome’s location in the Centre for Tropical Disease suggests something strange about the relationship between biomedical research and clinical practice, something that perhaps appears even more ominous in a developing country like Vietnam. One telling, albeit unofficial stat that was given to me: the average custodian at Oxford University earns more than the typical Vietnamese doctor. HCMC’s Hospital for Tropical Disease is a place of unders. Staff is underpaid, the hospital is undersupplied, disease goes underreported. Indeed, the only thing not in short supply seems to be the overwhelming number of patients in need of HTD’s services.
So when we realize that Wellcome’s doctors are paid far more than their Vietnamese counterparts, we’re left with a sour taste in our mouths.
At first glance, this means that money is being channeled from patient care to people whose principal job is not to heal, but rather to crank out paper after paper in European and American academic journals. And there’s some truth to this. Most work done at Wellcome won’t immediately improve patient outcomes, just as most research done in the States won’t result in the cure for cancer. In resource poor settings like Vietnam, then, it seems that money would be better spent investing in improving patient care or training more doctors. Right?
But to think so idealistically is to ignore basic economic principles. Frivolous though investment in research may seem in 90% of cases, few would deny that the remaining 10% does justify that spending. Given how interdisciplinary it is, biomedicine is a field that requires the best and brightest individuals. And in order to attract the best and brightest, there needs to be some incentive. After all, the altruistic lure of helping your fellow man may not be enough, even when one throws promises of steaming bowls of Vietnamese pho into the mix.
To understand how important this incentive is, it may be best to look at how medicine works when it isn’t there. Many people have criticized pharmaceutical companies for turning a blind eye to the millions of patients in developing countries who can’t afford their life-saving products. Between 1975 and 1999, fewer than 1% of newly designed therapeutic drugs were intended to treat tropical diseases. (Interestingly enough, a number of new medications were created to treat canine arthritis during this same time.) Research is time-intensive and expensive, and eventually there needs to be a reward for that investment, whether it comes from the wallets of sick patients or pet-owners.
This is how the market will inevitably behave, unless we tweak the incentives. The simple truth is that the individuals capable of developing the cure for cancer could make loads of money as lawyers or investment bankers instead. But it isn’t easy curing cancer; research can take years to pay off, and there needs to be an immediate incentive to attract these individuals now.
So then back to Vietnam, where tropical disease is a bigger deal than canine arthritis and this disconnect between research and clinical practice becomes much more tragic. Are we justified in funding a research team of expat doctors while Vietnamese patients suffer next door? Is medicine a business or a basic human right? Is a bird in the hand worth two in the bush?
You could argue these questions all day and not come up with a clear answer. Whatever your view, few would contest that the attention being given to tropical diseases is a good thing in any form. Ultimately, the fruitfulness of Wellcome’s research will depend on whether or not it can continue to attract the brightest researchers, and for now, there’s only one way to do that.

